Pfizer

The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.
July 20, 2022

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

By Leigh MacMillan
January 24, 2022

Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines

Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.

By Jessica Pasley
October 7, 2021

Boosta-Palooza

VUMC employees were able to receive a single booster dose of the Pfizer COVID-19 vaccine at this week’s Boosta-Palooza event.

By VUMC News and Communications
March 27, 2014

Flu boosts pneumococcal colonization

Influenza and parainfluenza infections – but not other respiratory viruses – increase the risk of acquiring pneumococcal bacteria, the most common cause of severe pneumonia.

By VUMC News and Communications
stopwatch
June 28, 2011

Inflammation relief: what’s the delay?

New research offers hope for patients needing the anti-inflammatory benefits of glucocorticoids without the adverse side effects associated with them.

By VUMC News and Communications